CBER director Peter Marks outlines the top priorities at the Center this year that include updating the Center’s tissue guidance to reduce the risk of infectious disease transmission, applying the accelerated approval pathway to rare disease gene therapies, and providing general guidance on platform technologies.
Federal Register
Lab Values for Cancer Trial Eligibility Guide
Federal Register notice: FDA makes available a draft guidance entitled “Cancer Clinical Trial Eligibility Criteria: Laboratory Values.”